Partner Content Partner Content 10 Key Reasons to attend SMi’s 10th Annual Biosimilars Confe... 10 Key Reasons to attend Biosimilars
Partner Content Partner Content Michel Mikhail invites Biosimilar experts to attend SMi’s 10... Michel Mikhail invites Biosimilar experts to attend SMi
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.